Skip to main content
Premium Trial:

Request an Annual Quote

William Sullivan, Kevin Johnson, Giannni Garotta, Ennio Ongini, Randy Jones

Premium

William Sullivan has been ap-pointed vice president of diagnostics operations at Ciphergen’s new diagnostics division. Before joining Ciphergen, he was vice president of diagnostic manufacturing at Visible Genetics. Sullivan holds an AB degree from the College of the Holy Cross and attended graduate school at the University of Pennsylvania.


Kevin Johnson and Giannni Garotta have joined European venture capital firm Index Ventures as executives in residence, and Ennio Ongini as venture advisor. Johnson was most recently chief technology officer of Cambridge Antibody Technologies. Garotta used to be vice president for academic collaborations at Serono. Ongini is cur-rently head of discovery at Nicox.


Randy Jones has been named director of toxicology for the Arkansas discovery and development services division of Charles River Laboratories. Jones previously held a regulatory affairs management position at Primus. Prior to that, he spent 10 years as senior toxicologist at Bayer. He holds a PhD from the University of Georgia and a doctorate of veterinary medicine from Iowa State University.

 

 

The Scan

Vaccine Update Recommended

A US Food and Drug Administration panel recommends booster vaccines be updated to target Omicron, CNBC reports.

US to Make More Vaccines for Monkeypox Available

The US is to make nearly 300,000 vaccine doses available in the coming weeks to stem the spread of human monkeypox virus, according to NPR.

Sentence Appealed

The Associated Press reports that Swedish prosecutors are appealing the sentence given to a surgeon once lauded for transplanting synthetic tracheas but then convicted of causing bodily harm.

Genome Biology Papers on COVID-19 Effector Genes, Virtual ChIP-seq, scDART

In Genome Biology this week: proposed COVID-19 effector genes, method to predict transcription factor binding patterns, and more.